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Objectives: The aim of this study was to evaluate the appropriateness of piperacillin/tazobactam 
(Tazocin®; Pfizer, New York, NY) usage in our hospital.
Subjects and methods: This retrospective study was designed to involve all patients admitted 
to Hamad General Hospital and prescribed piperacillin/tazobactam as an empiric therapy 
from January 1 to March 31, 2008. The medical records of such patients were retrospectively 
reviewed and studied.
Results: During this period, 610 prescriptions were ordered for 596 patients. The main   indication 
for initiation of Tazocin was sepsis (207/610; 34%). The overall rate of appropriateness of 
empirical therapy was 348/610 (57%). Most of the inappropriate prescriptions were in cases of 
aspiration pneumonia and abdominal infections, with inappropriate prescriptions found mostly in 
surgical wards (86%) and the surgical intensive care unit (66.7%). Septic work-up results showed 
positive cultures in 57% (345/610) of cases. There were 198/254 prescriptions (78%) where 
antibiotics were changed according to the sensitivity data to narrow-spectrum antimicrobials. 
In 56/254 (22%) cases, pathogens were susceptible to narrow-spectrum antibiotics even though 
piperacillin/tazobactam was continued.
Conclusion: Our study showed that there was an injudicious use of piperacillin/tazobactam 
at our hospital, evidenced by the significant number of inappropriate empiric prescriptions and 
inappropriate drug modifications, based on the results of microbial cultures and antibiograms.
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Introduction
The broadest-spectrum antibiotics, such as fourth-generation cephalosporins, 
piperacillin/tazobactam (Tazocin®; Pfizer, New York, NY), and carbapenems, play an 
important role in the empiric therapy of serious infections. Misuse of these antibiotics 
is common and costly,1 as physicians often opt for broad-spectrum antibiotics when 
a narrower-spectrum agent would suffice.2 Over-reliance on broad-spectrum agents 
is also thought to be an important contributor to growing worldwide antimicrobial 
resistance.3 Many hospitals implement a range of measures to address these growing 
problems. One common measure is to adopt an antibiotic formulary and guidelines.4 
In our hospital, the therapeutic committee has issued an antibiotic policy.5 Other 
methods include supervision of antibiotic use by infectious disease consultants and/or 
clinical pharmacists, provision of continuing education regarding appropriate anti-
microbial drug use, implementation of automatic stop orders, and drug utilization 
evaluation.1,6
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Piperacillin/tazobactam is a β-lactam/β-lactamase 
inhibitor combination with a broad spectrum of antibacte-
rial activity against most Gram-positive and Gram-negative 
aerobic bacteria and anaerobic bacteria. Tazocin is effective 
and well tolerated in patients with lower respiratory tract 
infections, intra-abdominal infections, skin and soft tissue 
infections, and febrile neutropenia.7 Tazocin was approved by 
the therapeutic committee at Hamad General Hospital many 
years ago. Since that time, it has become one of the most-
prescribed pharmaceuticals in our hospital. In 2008, there 
were 2600 prescriptions of this drug. The use of antimicrobial 
agents has been widely assessed in hospitals by measuring 
quantitative pharmacy data to calculate the number of defined 
daily doses per occupied bed-days, but this measurement 
does not indicate whether therapy was appropriate. Because 
of its high prescription volume and spiraling expenditure, 
this study was conducted to evaluate the appropriateness of 
Tazocin usage in our hospital.
Subjects and methods
Design and setting
This retrospective study was conducted at Hamad General 
Hospital, which is a tertiary center that covers all specialties 
except for hematology, oncology, and obstetrics. It includes 
six intensive care units that provide a full range of clinical 
services for different subspecialties.
Patients, diagnostic criteria,  
and data source
The study involved all patients admitted to Hamad General 
Hospital and prescribed Tazocin as an empiric therapy during 
a period of three months from January 1, 2008 to March 31, 
2008, after being approved by the Medical Ethics Committee 
of the Hamad Medical Corporation. Patients were identified 
from the hospital’s pharmacy records and then the medical 
records of these patients were retrospectively reviewed and 
studied. During this period, 981 prescriptions of Tazocin 
were ordered for 876 patients. Only 371 of these prescrip-
tions were used to treat documented infections, whereas 610 
were prescribed initially as empiric therapy for suspected 
infections. These 610 cases were the subject of this study. 
Tazocin prescription was deemed appropriate if:
•	 it was selected as an empirical therapy in accordance with 
hospital’s guidelines5
•	 it was switched to an alternative antibiotic with a narrow 
spectrum after receipt of culture and susceptibility data
•	 the dose was in accordance with the hospital’s guidelines
•	 it was discontinued once culture data were negative
•	 it was discontinued once culture data showed a resistant 
organism.
If one of these conditions was not met, the prescription was 
considered inappropriate.
Data collection and analysis
The medical record of each patient was reviewed to retrieve 
patient demographic data and provisional diagnosis, and 
whether Tazocin as empirical therapy was appropriate 
according to the criteria above. The gathered information 
was transferred to the computer utilizing the Epi InfoTM 2000 
(Centers for Disease Control and Prevention, Atlanta, GA) 
software. Data were analyzed using simple statistics.
Results
During the period of study, 610 prescriptions were ordered for 
596 patients. The mean age of patients was 62.8 ± 16.8 years 
(25–93 years) and 79% (483/610) of them were male.
Table 1 describes the indications for which Tazocin was 
prescribed as an empiric treatment for suspected infections. 
The main indication for initiation of Tazocin was sepsis 
(207/610; 34%). Table 2 describes the appropriateness of 
Tazocin therapy. The overall rate of appropriateness of 
empirical therapy was (348/610; 57%). Most of the inappro-
priate prescriptions were in cases of aspiration pneumonia, 
peritonitis, acute cholecystitis, community-acquired pneumo-
nia, skin and soft tissue infections, and community-acquired 
urinary tract infections (Table 1).
Patients were distributed in different wards. The wards 
in which inappropriate prescription patterns were most 
  frequently observed included the surgical ward (86%) and the 
surgical intensive care unit (66.7%). Table 3 summarizes the 
distribution of the patients in different wards in the hospital 
in relation to appropriate use of Tazocin.
Septic work-up results showed positive cultures in 
57% (345/610) of episodes. The most frequently identified 
microorganisms were Gram-negative bacilli, which included 
E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, 
Acinetobacter species, and others. The identified micro-
organisms showed resistance to Tazocin in 30/345 cases 
(8.7%) and they were sensitive to Tazocin as well as other 
antimicrobials with a narrow spectrum in 254/345 cases 
(73.6%). However, the isolates were sensitive to Tazocin 
and other broad-spectrum antibiotics (cefepime and mero-
penem) only in 61/345 cases (17.7%). There were 198/254 
prescriptions (78%) where antibiotics were changed accord-
ing to the sensitivity data to narrow-spectrum antimicrobials, 
whereas in 56/254 cases (22%) pathogens were susceptible 
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showed emerging resistance to Tazocin among Gram-
negative microorganisms, is alarming and prompted us to 
conduct this study, which is the first to evaluate the usage 
of Tazocin in our hospital.
The choice of Tazocin as an empiric therapy depends on 
the knowledge of the most common causative bacteria in 
different conditions and the reported efficacy of this drug. 
Therefore, to regulate empirical usage of antibiotics, many 
institutes such as ours have developed a set of guidelines. In 
our hospital these guidelines have been updated periodically 
by consensus among experts (microbiologists, clinicians, and 
pharmacists) based on local studies and annual surveillance. 
Despite implementation of these guidelines, there were a 
significant number of inappropriate empiric prescriptions of 
Tazocin, most probably due to physicians being unaware of 
the hospital’s guidelines and/or their difficulty in recalling 
these guidelines during busy working hours. Other reasons for 
inappropriate empirical therapy include uncertainty of differ-
ential diagnoses; complex comorbidities; and lack of training, 
experience, or confidence of the physicians in charge.
As noted, 73.6% of positive-culture cases were suitable for 
modification to narrow-spectrum antimicrobials, but 22% of 
the prescriptions remained unchanged. Moreover, three pre-
scriptions were continued despite the microbiological results 
showing that the pathogens were resistant to the drug. These 
findings may be attributed to physicians’ lack of knowledge or 
to their overlooking the culture results and antibiotic sensitiv-
ity profiles.9 Modification of empiric antibiotic therapy based 
on the results of microbial cultures and antibiograms will help 
to reduce costs, decrease the incidence of superinfection, and 
minimize the development of resistance.10
Table 1 Conditions for which Tazocin® was prescribed empirically and appropriateness of prescription
Provisional diagnosis Total 
(column)
Appropriate Inappropriate Total 
(row)
Community-acquired UTI 49 (8.0%) 13 (25.0) 36 (75.0) 49 (100.0)
Peritonitis 24 (4.0%) 0 (0.0) 24 (100.0) 24 (100.0)
Acute cholycystitis 12 (2.0%) 0 (0.0) 12 (100.0) 12 (100.0)
Aspiration pneumonia 49 (8.0%) 0 (0.0) 49 (100.0) 49 (100.0)
Community acquired pneumonia 43 (7.0%) 0 (0.0) 43 (100.0) 43 (100.0)
Febrile neutropenia 12 (2.0%) 12 (100.0) 0 (0.0) 12 (100.0)
Line related sepsis 55 (9.0%) 49 (89.0) 6 (11.0) 55 (100.0)
nosocomial pneumonia 61 (10.0%) 61 (100.0) 0 (0.0) 61 (100.0)
nosocomial UTI 12 (2.0%) 6 (50.0) 6 (50.0) 12 (100.0)
Peritonitis with CAPD 12 (2.0%) 0 (0.0) 12 (100.0) 12 (100.0)
SBP 12 (2.0%) 0 (0.0) 12 (100.0) 12 (100.0)
Sepsis 207 (34.0%) 207 (100.0) 0 (0.0) 207 (100.0)
Skin and soft tissue infection 31 (5.0%) 0 (0.0) 31 (100.0) 31 (100.0)
Others 31 (5.0%) 0 (0.0) 31 (100.0) 31 (100.0)
Total 610 (100.0%) 348 (57.0) 262 (43.0) 610 (100.0)
Abbreviations: UTI, urinary tract infection; CAPD, continuous ambulatory peritoneal dialysis; SBP, spontaneous bacterial peritonitis.
Table 2 Summary of Tazocin® usage appropriateness
Data Appropriate Inappropriate
Initial use as empirical therapy  
in accordance with hospital’s  
guidelines
348/610 (57%) 262/610 (43%)
Switching to an alternative  
antibiotic with narrow  
spectrum after receipt of  
culture and susceptibility data
198/254 (78%) 56/254 (22%)
Dosing in accordance with  
the hospital’s guidelines
610 (100%) 0.0%
Dose adjustment in renal  
impairment
213/213 (100%) 0.0%
Discontinuation once culture  
data were negative
105/265 (40%) 160/265 (60%)
Discontinuation once culture  
data showed resistant organism
27/30 (90%) 3/30 (10%)
to narrow-spectrum antibiotics even though Tazocin was 
continued, reflecting inappropriate usage of this antibiotic. 
In a few prescriptions (3/254; 1.2%), Tazocin was continued 
despite the microbiological results showing that the patho-
gens were resistant to the drug. Among cultured negative 
cases (265/610; 43%), Tazocin was continued in most cases 
(160/265; 60%). The reasons for Tazocin continuation despite 
negative cultures were unclear. The dose adjustment of 
Tazocin was achieved perfectly in all patients. Table 2 sum-
marizes the appropriateness of Tazocin therapy.
Discussion
The over-utilization of Tazocin compared with other 
  broadest-spectrum antibiotics, which increases the prob-
ability of the emergence of resistant organisms,3 in addition 
to the available evidence from a previous study8 that has 
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Interestingly, many initial empirical therapy courses 
(265/610; 43%) were found to be culture-negative, which is 
higher than one would expect. This could be explained partly 
by the fact that the majority of our patients were elderly and 
presented with vague symptoms mimicking sepsis. These 
vague symptoms are usually attributed to noninfectious 
disorders such as renal impairment, hyperglycemia, 
metabolic acidosis, starvation, and dehydration.
Among cultured negative cases, Tazocin was continued 
in most cases (160/265; 60%). This is similar to the report of 
Ahkee et al,11 who reported that one of the common reasons 
for prescribing antibiotics inappropriately is giving them 
to patients without documented infection. The reasons for 
Tazocin continuation in our study despite negative cultures 
were unclear. This requires more study.
This study has some limitations. Firstly, it was retrospective 
rather than prospective and this design did not allow us to 
obtain additional details, such as the reason for Tazocin con-
tinuation despite negative cultures. Secondly, we focused on 
cases occurring over a 3-month period, which may not have 
been enough time for accurate judgment. Thirdly, due to a 
lack of studies on Tazocin worldwide, we could not bench-
mark and compare our results with other centers.
Conclusion
Our study has shown that there were unjustified prescriptions at 
our hospital, evidenced by the significant number of inappropri-
ate empiric prescriptions and inappropriate drug modification 
based on the results of microbial cultures and antibiograms. We 
suggest further prospective studies to confirm these findings 
and to explain the reasons for   Tazocin continuation despite 
negative cultures. To improve the appropriateness of Tazocin 
prescription in our hospital, we recommend:
•	 dissemination of the implemented guidelines, via 
widespread publication and staff education
•	 rationalization of the use of Tazocin in different hospital 
units, with a special focus on both initial empirical therapy 
and modification of this therapy once   microbiological 
results become available
•	 ongoing annual surveillance, to monitor progression of 
resistance to this drug
•	 restrictive measures, ie, infectious disease team consultation 
should be mandatory prior to prescription of this drug.
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Table 3 Departments in which the drug was prescribed empirically
Ward Total 
(column)
Appropriate Inappropriate Total 
(row)
CCU 31 (5.0%) 25 (80.4%) 6 (19.6%) 31 (100.0%)
Medical 341 (56.0%) 183 (53.6%) 158 (46.4) 341 (100.0%)
MICU 159 (26.0%) 116 (73.0%) 43 (27.0%) 159 (100.0%)
SICU 18 (3.0%) 6 (33.3%) 12 (66.7%) 18 (100.0%)
Surgical 43 (7.0%) 6 (14.0%) 37 (86.0%) 43 (100.0%)
TICU 18 (3.0%) 12 (66.7%) 6 (33.3%) 18 (100.0%)
Total 610 (100%) 248 (57.0%) 262 (43.0%) 100 (100.0%)
Abbreviations: CCU, coronary care unit; MICU, medical intensive care unit; SICU, surgical intensive care unit; TICU, trauma intensive care unit.
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